Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study

European Journal of Neurology

Volumn 22, Issue 3, 2015, Pages 457-463

  Reinoso, G ^a   Allen, J C ^a   Au, W L ^b   Seah, S H ^b   Tay, K Y ^b   Tan, L C S ^b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Age; Cognition; Disease subtype; Gender; Motor; Parkinson's disease; Progression; Unified PD Rating Scale (UPDRS)

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

ADULT; AKINESIA; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE COURSE; EVOLUTION; FEMALE; FOLLOW UP; HOEHN AND YAHR SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; SEX DIFFERENCE; TIME;

AGED; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROGNOSIS; SEX FACTORS; TIME FACTORS;

EID: 84922718224     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12476     Document Type: Article

References (30)

1. Post B, Merkus MP, de Haan RJ, Speelman JD; CS Group. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1839-1851.
2. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59: 1724-1728.
3. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67: 300-307.
4. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005; 65: 1436-1441.
5. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-1615.
6. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999; 56: 334-337.
7. McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol 1995; 52: 565-570.
8. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343-348.
9. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
10. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002; 17: 867-876.
11. Vogt T, Kramer K, Gartenschlaeger M, Schreckenberger M. Estimation of further disease progression of Parkinson's disease by dopamine transporter scan vs clinical rating. Parkinsonism Relat Disord 2011; 17: 459-463.
12. Rossi C, Frosini D, Volterrani D, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol 2010; 17: 626-630.
13. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008; 255: 255-264.
14. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 968-975.
15. Garcia Ruiz PJ, Meseguer E, Del Val J, Vazquez A, Sanchez Bernardos V, Vazquez A. Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 2004; 27: 49-52.
16. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-2417.
17. Lopez IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson's disease: ten year follow-up study. Mov Disord 2010; 25: 2735-2739.
18. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006; 63: 584-588.
19. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007; 22: 938-945.
20. Poewe W. Clinical measures of progression in Parkinson's disease. Mov Disord 2009; 24(Suppl 2): S671-S676.
21. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
22. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
23. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969; 101: 59-68.
24. Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 2010; 25: 710-716.
25. Shulman LM. Gender differences in Parkinson's disease. Gend Med 2007; 4: 8-18.
26. Dluzen DE, McDermott JL. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann N Y Acad Sci 2000; 914: 112-126.
27. Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology 2013; 80: 627-633.
28. Schapira AH, Schrag A. Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol 2011; 7: 247-248.
29. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957.
30. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 379-382.